News | January 29, 2010

First Commercial Implants of ATS 3f Enable Aortic Bioprosthesis Performed

Jan. 25, 2010 —  The first commercial implants of the ATS 3f Enable Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, M.D., Mario Stalder, M.D., and professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.

The ATS 3f Enable valve is the first approved for commercial use that is implanted using a sutureless technique. The Enable valve combines the ATS 3f Aortic Bioprosthesis with more than eight years of proven clinical performance and a self-expanding Nitinol frame to hold the valve in its optimal position eliminating the need for conventional sutures. This design allows the Enable valve to be folded into a small diameter and placed through a minimally invasive incision. The Enable valve preserves native stress distribution and provides a large orifice area with laminar flow for excellent hemodynamics.

Professor Thierry Carrel, chief of cardiac surgery at the University of Berne said, "The implants went smoothly. There were no paravalvular leaks and the valves provide excellent hemodynamic performance with low single digit gradients. The Enable valve will help us expand our number of minimally invasive procedures."

"The Enable valve proves to be a true competitor for TAVI (Transcatheter Aortic Valve Implantation) because the diseased valve is removed, we can directly visualize the placement of the new valve thereby obtaining clinical outcomes similar to conventional procedures," he added. "TAVI can be considered palliative whereas Enable is restorative."

The company is continuing to develop sutureless tissue valve technology for use in beating heart procedures based in part on the characteristics of the next generation of Enable valves. First in human studies of these novel technologies are targeted for 2010.

Commercialization of a beating heart solution could occur within one to two years thereafter. An Enable valve that is compatible in beating heart procedures would enlarge the company's market opportunity by providing a solution for those patients who are poor candidates to endure conventional surgery or prefer a more minimally invasive solution.

For more information:

Related Content

Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
Overlay Init